ArticleScientific data2025
Comprehensive multi-phase 3D contrast-enhanced CT imaging for primary liver cancer.
Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Three-class radiomic differentiation of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma on multiphasic contrast-enhanced CT.Abdominal radiology (New York) · 2026Article
- Primary malignant peripheral nerve sheath tumor of the liver: a case report and literature review.Frontiers in oncology · 2026Article
- Large-Scale CT Dataset with Complete Phase Coverage Advances Primary Liver Cancer AI Diagnostics.Radiology. Imaging cancer · 2025Article
- Fourier-modulated CLIP for zero-shot vehicle counting.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Primary liver cancer is a significant global health issue with high incidence and mortality rates worldwide. Accurate diagnosis and classification of its subtypes are crucial for choosing the right treatment options and improving patient outcomes. Contrast-enhanced computed tomography (CECT) is known for its high sensitivity and specificity in diagnosing liver cancer. However, publicly available datasets of liver cancer CECT scans are limited and often do not fully cover all subtypes or include complete CT scan phases. We hypothesize that using 3D CECT images with complete scan phases can help develop and validate diagnostic and segmentation models for primary liver cancer. Therefore, we created a CECT dataset with annotated liver and lesion areas. This dataset includes 278 cases of liver cancer, featuring hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma, along with CECT images from 83 non-liver cancer subjects. It contains over 50,000 layers of liver cancer lesion images. We believe this dataset can offer valuable support for developing and validating models for classifying and segmenting primary liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.